MREO vs. ADPT, SRPT, TARS, IMCR, ARQT, SPRY, SDGR, OCUL, VERA, and BHVN
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), Tarsus Pharmaceuticals (TARS), Immunocore (IMCR), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Mereo BioPharma Group vs. Its Competitors
Mereo BioPharma Group (NASDAQ:MREO) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.
62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 5.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Mereo BioPharma Group presently has a consensus price target of $7.20, indicating a potential upside of 335.05%. Adaptive Biotechnologies has a consensus price target of $10.57, indicating a potential downside of 6.61%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Adaptive Biotechnologies.
Mereo BioPharma Group has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -74.84%. Adaptive Biotechnologies' return on equity of -62.79% beat Mereo BioPharma Group's return on equity.
In the previous week, Mereo BioPharma Group and Mereo BioPharma Group both had 11 articles in the media. Adaptive Biotechnologies' average media sentiment score of 0.56 beat Mereo BioPharma Group's score of -0.23 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.
Mereo BioPharma Group has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.
Mereo BioPharma Group has higher earnings, but lower revenue than Adaptive Biotechnologies. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Summary
Adaptive Biotechnologies beats Mereo BioPharma Group on 9 of the 16 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
This page (NASDAQ:MREO) was last updated on 7/15/2025 by MarketBeat.com Staff
